Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022308 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00022308: Completed Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT00022308 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022308, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have locally advanced non-small cell lung cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
What the finished NCT00022308 record still lists
NCT00022308 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00022308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00022308 about?
NCT00022308 is a clinical study titled "Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effec...
What is the current status of trial NCT00022308?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00022308?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00022308?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia